Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;22(4):677-684.
doi: 10.1007/s42000-023-00488-w. Epub 2023 Sep 13.

Management of type 2 diabetes in the new era

Aris Liakos  1   2 , Thomas Karagiannis  3   4 , Ioannis Avgerinos  3   4 , Konstantinos Malandris  3   4 , Apostolos Tsapas  3   4   5 , Eleni Bekiari  3   4
Affiliations
Review

Management of type 2 diabetes in the new era

Aris Liakos et al. Hormones (Athens). 2023 Dec.

Abstract

Purpose: Management of type 2 diabetes is advancing beyond glycemic control and is increasingly based on cardiovascular risk stratification. This review summarizes recent advances in the field and identifies existing knowledge gaps and areas of ongoing research.

Methods: A bibliographic search was carried out in PubMed for recently published cardiorenal outcome trials, relevant guidelines, and studies on antidiabetic agents in the pipeline.

Results: Findings from cardiovascular outcome trials support the use of glucagon-like peptide 1 (GLP-1) receptor agonists or sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with established cardiovascular disease or multiple risk factors, although it as yet remains uncertain whether the benefits are transferable to patients at lower absolute cardiovascular risk. Additionally, robust evidence suggests that SGLT-2 inhibitors improve clinical outcomes for people with concomitant heart failure or chronic kidney disease. Gut hormone multiagonists will likely represent another major addition to the therapeutic armamentarium for morbidly obese individuals with diabetes. Moreover, nonalcoholic fatty liver disease is a common comorbidity and several liver outcome trials are awaited with great interest. Use of insulin as first-line injectable therapy has been displaced by GLP-1 receptor agonists. Once-weekly formulations of basal insulins along with combinations with GLP-1 receptor agonists are also under development and could increase patient convenience. Technologies of glucose sensors are rapidly evolving and have the potential to reduce the burden of frequent blood glucose measurements, mainly for patients treated with intensified insulin regimens.

Conclusion: Management of type 2 diabetes requires a holistic approach and recent breakthroughs are expected to improve the quality of care.

Keywords: Cardiovascular outcome trials; Glucagon-like peptide 1 receptor agonists; Obesity; Sodium-glucose cotransporter 2 inhibitors; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Avgerinos I, Papanastasiou G, Karagiannis T, et al. Ultra-rapid-acting insulins for adults with diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(10):2395–2401. doi: 10.1111/dom.14461. - DOI - PubMed
    1. Madenidou AV, Paschos P, Karagiannis T, et al. Comparative benefits and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2018;169(3):165–174. doi: 10.7326/M18-0443. - DOI - PubMed
    1. U.S. Food and Drug Administration. Guidance for Industry. Diabetes mellitus - evaluating cardiovscular risk in new antidiabetic therpaies to treat type 2 diabetes. https://downloads.regulations.gov/FDA-2008-D-0118-0029/content.pdf Accessed 1 June 2023
    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. - DOI - PubMed
    1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2022;65(12):1925–1966. doi: 10.1007/s00125-022-05787-2. - DOI - PMC - PubMed

MeSH terms